ProCE Banner Activity

Expert Panel Discussion 1: Best Practices to Proactively Address Treatment-Related AEs

Slideset Download
Download these slides from a series of live presentations to learn more about best practices to proactively address immunotherapy-related adverse events in melanoma designed for nurses and advanced practice healthcare professionals.

Released: January 31, 2022

Expiration: January 30, 2023

Share

Faculty

Kathleen Madden

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Suzanne McGettigan

Suzanne McGettigan, MSN, AOCN, ANP-BC

Nurse Practitioner, Clinical Manager
Division of Hematology-Oncology
Abramson Cancer Center
Penn Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Krista M. Rubin

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Kathy Madden, MSN, FNP-BC, AOCNP, APHN, has disclosed that she has received consulting fees from Novartis and Pfizer.

Suzanne McGettigan, MSN, AOCN, ANP-BC

Nurse Practitioner, Clinical Manager
Division of Hematology-Oncology
Abramson Cancer Center
Penn Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Suzanne McGettigan, MSN, AOCN, ANP-BC, has disclosed that she has received fees for non-CME/CE services from Bristol-Myers Squibb, Merck, and Pfizer.

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Krista M. Rubin, MS, RN, FNP-BC, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Eisai, and Merck.